Home / B4GALT1 Knockout Cell Lines

B4GALT1 Knockout Cell Lines

Gene: B4GALT1

Official Full Name: beta-1,4-galactosyltransferase 1provided by HGNC

Gene Summary: This gene is one of seven beta-1,4-galactosyltransferase (beta4GalT) genes. They encode type II membrane-bound glycoproteins that appear to have exclusive specificity for the donor substrate UDP-galactose; all transfer galactose in a beta1,4 linkage to similar acceptor sugars: GlcNAc, Glc, and Xyl. Each beta4GalT has a distinct function in the biosynthesis of different glycoconjugates and saccharide structures. As type II membrane proteins, they have an N-terminal hydrophobic signal sequence that directs the protein to the Golgi apparatus and which then remains uncleaved to function as a transmembrane anchor. By sequence similarity, the beta4GalTs form four groups: beta4GalT1 and beta4GalT2, beta4GalT3 and beta4GalT4, beta4GalT5 and beta4GalT6, and beta4GalT7. This gene is unique among the beta4GalT genes because it encodes an enzyme that participates both in glycoconjugate and lactose biosynthesis. For the first activity, the enzyme adds galactose to N-acetylglucosamine residues that are either monosaccharides or the nonreducing ends of glycoprotein carbohydrate chains. The second activity is restricted to lactating mammary tissues where the enzyme forms a heterodimer with alpha-lactalbumin to catalyze UDP-galactose + D-glucose <=> UDP + lactose. The two enzymatic forms result from alternate transcription initiation sites and post-translational processing. Two transcripts, which differ only at the 5' end, with approximate lengths of 4.1 kb and 3.9 kb encode the same protein. The longer transcript encodes the type II membrane-bound, trans-Golgi resident protein involved in glycoconjugate biosynthesis. The shorter transcript encodes a protein which is cleaved to form the soluble lactose synthase. [provided by RefSeq, Jul 2008]

Get A Quote
Products Background

Products

Catalog Number Product Name Species Gene Passage ratio Mycoplasma testing Price
KO37658 B4GALT1 Knockout cell line (HeLa) Human B4GALT1 1:3~1:6 Negative Online Inquiry
KO37659 B4GALT1 Knockout cell line (HCT 116) Human B4GALT1 1:2~1:4 Negative Online Inquiry
KO37660 B4GALT1 Knockout cell line (HEK293) Human B4GALT1 1:3~1:6 Negative Online Inquiry
KO37661 B4GALT1 Knockout cell line (A549) Human B4GALT1 1:3~1:4 Negative Online Inquiry

Background

B4GALT1 Gene Knockout Cell Lines represent a crucial tool in molecular biology research, specifically designed to facilitate the study of glycosylation, a fundamental post-translational modification influencing various cellular functions. These cell lines have been genetically engineered for the complete loss of function of the B4GALT1 gene, which encodes an enzyme responsible for synthesizing specific glycan structures important in cell signaling, adhesion, and immune responses.

The key mechanism through which the B4GALT1 knockout operates is the disruption of the glycosylation pathway. The absence of B4GALT1 results in the knockout of bioactive structures critical for normal cell biology, enabling researchers to dissect the role that glycan structures play in physiological and pathological contexts. By utilizing these cell lines, scientists can meticulously investigate the implications of altered glycosylation in processes such as tumor progression, immune evasion, and pathogen recognition.

In clinical and research settings, B4GALT1 Gene Knockout Cell Lines offer significant scientific importance. They provide a standardized model for studying diseases where glycosylation plays a role, and they can aid in the development of therapeutics targeting glycan-mediated pathways. Furthermore, these cell lines serve as a fundamental component in advancing the understanding of cell-cell and cell-matrix interactions, contributing to the overall quest for novel disease interventions.

What sets B4GALT1 Gene Knockout Cell Lines apart from other available cellular models is their precise genetic modification that ensures consistent expression of knockout characteristics across different cultures and experiments. This reliability enhances experimental reproducibility and allows researchers to draw firm conclusions from their findings.

For researchers and clinicians seeking to deepen their understanding of cellular behavior and disease mechanisms related to glycosylation, the B4GALT1 Gene Knockout Cell Lines are an invaluable asset. They not only streamline experimental design but also accelerate the translation from discovery to application in therapeutic settings.

At our company, we pride ourselves on our commitment to providing high-quality, precisely engineered biological products that empower scientific discovery. Our expertise in genetic modification and cell line development ensures that researchers have access to the best tools for advancing their work.

Please note that all services are for research use only. Not intended for any clinical use.

Get a free quote

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

0

There is no product in your cart.